According to a new report Global Cardiac Biomarkers Testing Market, published by KBV research, The Global Cardiac Biomarkers Testing Market size is expected to reach $16.2 billion by 2025, rising at a market growth of 11.4% CAGR during the forecast period.
The North America market dominated the Global Creatine Kinase (CK-MB) Market by Region in 2018, growing at a CAGR of 9.9 % during the forecast period. The Europe market is expected to witness a CAGR of 10.3% during (2019 - 2025). Additionally, The Asia Pacific market is expected to witness a CAGR of 12% during (2019 - 2025).
The Myocardial Infarction market dominated the Global Cardiac Biomarkers Testing Market by Application in 2018, growing at a CAGR of 11 % during the forecast period. The Congestive Heart Failure market is expected to witness a CAGR of 12.5% during (2019 - 2025). Additionally, The Acute Coronary Syndrome market is expected to witness highest CAGR of 10.9% during (2019 - 2025).
The Laboratory Testing market dominated the Global Cardiac Biomarkers Testing Market by Location of Testing in 2018, growing at a CAGR of 10.3 % during the forecast period. The Point of Care Testing market is expected to witness highest CAGR of 13.6% during (2019 - 2025).
Full Report: https://www.kbvresearch.com/cardiac-biomarkers-testing-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Trivitron Healthcare Pvt. Ltd., ABBOTT Laboratories, Siemens AG, Becton, Dickinson AND Company, Bio-Rad laboratories, Inc., Randox Laboratories Limited, Danaher Corporation, Thermo Fisher Scientific, Inc., Johnson and Johnson and Quidel Corporation.
By Type
By Application
By Location of Testing
By Geography
Companies Profiled
Unique Offerings from KBV Research
Unique Offerings 
